OncLive TV

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

Michael Wang, MD, discusses the efficacy of KTE-X19 in low- and high-risk patients with relapsed/refractory mantle cell lymphoma as part of the phase 2 ZUMA-2 trial.

Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Paul G. Richardson, MD, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Fred Saad, MD, FRCS, discusses unique characteristics of apalutamide compared with other antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

John Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.

Félix Guerrero-Ramos, MD, PhD, FEBU, discusses the role of Bacillus Calmette-Guerin in the treatment of patients with non-muscle invasive bladder cancer.

Scott S. Tykodi, MD, PhD, discusses the efficacy of dual checkpoint blockade in renal cell carcinoma.

Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.

Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.

Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.

Nabil F. Saba, MD, FACP, discusses the future of treatment in head and neck cancer.

John Kuruvilla, MD, FRCPC, discusses the broad utility of pembrolizumab in Hodgkin lymphoma.

Brian T. Hill, MD, PhD, discusses the safety profile of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Alexandra Sokolova, MD, discusses the challenges of germline testing in patients with metastatic prostate cancer. 

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

William W. Tseng, MD, discusses the potential role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma.

Fred Saad, MD, FRCS, discusses the safety profile of apalutamide in nonmetastatic castration-resistant prostate cancer.

Hun Ju Lee, MD, discusses B-cell receptor targeting in relapsed/refractory mantle cell lymphoma.

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.